With the upcoming triggers expected from possibility of inorganic expansion, growth in textile segment, new sustainable products the brokerage rolls forward our valuation to FY27E with a price to earning of 22 times on an earnings per share Rs 16.6 to arrive at a target price of Rs 366/share.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Deven Choksey Report
Fineotex Chemical Ltd. posted muted sales and volume growth for Q3 FY25; primarily driven lower by a challenging demand environment in FMCG, textiles segment grew by 20% in volumes, exports also haven’t been able to keep up pace due to issues in Bangladesh.
On a nine-month basis revenues remained stable coming in at Rs 4,135 million (-0.6% YoY), Ebitda margin was also flat at 26% declining by 26 bps.
Fineotex Chemical has launched 30 new products in textile chemicals. Fineotex Chemical has also announced the launch of their water-based mosquito repellant “Aquastrike”, we believe water treatment and oil and gas verticals will drive growth going forward.
We introduce FY27 estimates, with a three-year revenue CAGR of 16% and Ebitda margins of 28%. Considering upcoming positive triggers for the company:
buoyancy in the textile markets
upcoming inorganic expansions,
new sustainable product launches,
we value the company at 20x FY27E EPS of Rs 16.6 to arrive at a target price of Rs 366 implying an upside of 43.9%.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

Why Is Apollo Hospitals Stock Poised For Re-Rating? Read PL Capital Report


'Buy' Kalpataru Projects Shares Maintains Axis Securities On Growth Outlook — Check Target Price


Stock Picks Today: BSE, Titan, LIC, AU Small Finance Bank On Brokerages' Radar

RBI MPC Monetary Policy Review — Bar For The Next Cut Remains High: Read Dolat Capital Report
